Indications & formulation #
Adult depression and generalized anxiety disorder. This reference covers the selected formulation; other indications and products need their own evidence.
Dose reference #
Adult educational reference · Oral tablet · United States. The clinician selects treatment after assessment; this page does not calculate or change a prescription.
Start 10 mg once daily; if indicated, increase after at least one week to a maximum 20 mg/day.
Contraindications & important cautions #
MAOIs and pimozide are contraindicated. Assess QT-related risk, serotonergic combinations, sodium and bleeding risk.
Selected important cautions; consult the full product information for all contraindications and warnings.
Adverse effects #
Gastrointestinal and sexual effects, activation, hyponatraemia and QT-related concerns in susceptible settings.
Interactions #
Reconcile serotonergic and QT-prolonging medicines and relevant metabolic inhibitors; organ function and formulation matter.
Monitoring #
Assess mood activation, function and tolerability; ECG/electrolyte review is guided by cardiac risk and local product instructions.
Special populations #
Most older adults and patients with hepatic impairment use 10 mg/day. Severe renal impairment lacks an established dose recommendation.
Adult scope. Pregnancy, breastfeeding and pediatric use require the exact product’s population-specific guidance and individual assessment.
Discontinuation, restarting & counseling #
Use a gradual reduction with review of withdrawal symptoms.
Condition-specific prescribing #
Additional indication-specific records retain their own formulation and source context.
Escitalopram
Generalised anxiety disorder
Adults · Immediate-release tablets · Oral · United Kingdom product information
- Starting dose
- 10 mg once daily.
- Titration
- Increase according to response and tolerability within the label range; a fixed increment is not specified in this UK SmPC.
- Treatment range / target
- 10–20 mg/day.
- Maximum / limits
- 20 mg/day for ordinary adults; lower limits apply below.
- Trial & duration
- Reevaluate benefit and dose regularly; continuation guidance below.
- Monitoring
- Activation, suicidality, sodium when indicated, bleeding and QT-related vulnerability.
- Population & organ-function adjustments
- Age >65: start 5 mg/day, maximum 10 mg/day. Mild/moderate hepatic impairment: 5 mg/day for 2 weeks, then up to 10 mg/day. Severe renal/hepatic impairment needs caution.
- Important cautions
- Avoid MAOIs and known QT prolongation or contraindicated QT-prolonging combinations.
Brands & products #
Historical catalogue observations. Prices and catalogue presence do not establish current availability or Indian approval.
Reference coverage #
Structured summary of selected adult uses, not an exhaustive monograph. Indian product authorization and local prescribing requirements have not been reconciled.
References · 2
- Escitalopram — Oral tablet — selected prescribing information · United States · Checked 2026-10-27 · Selected formulation: Oral tablet · Supports indications, dose, cautions, adverse effects, interactions, monitoring, special populations and stopping. Source sections: Indications and usage; Dosage and administration; Contraindications; warnings and precautions; Use in specific populations; patient counseling
- Escitalopram tablets: SmPC sections 4.2–4.5 · United Kingdom product information · Checked 2026-10-26 · Supports: Escitalopram — Generalised anxiety disorder (Immediate-release tablets)